What is CellProthera?
CellProthera is a pioneering biotechnology firm dedicated to advancing cardiac regenerative therapy. The company's core innovation lies in its proprietary bioproduction platform, which cultivates CD34+ cells, termed ProtheraCytes. These cells are engineered to promote angiogenesis and revascularization, crucial processes for restoring blood flow to ischemic tissues. CellProthera's therapeutic approach involves the direct injection of ProtheraCytes into patients who have experienced severe myocardial infarction, with the ultimate goal of improving long-term cardiac function and enabling patients to return to a normal life. The company's focus on personalized medicine targets individuals suffering from severe heart failure post-myocardial infarction, positioning it at the forefront of innovative cardiovascular treatments.
How much funding has CellProthera raised?
CellProthera has raised a total of $8.9M across 1 funding round:
Private Equity
$8.9M
Private Equity (2017): $8.9M, investors not publicly disclosed
What's next for CellProthera?
With the recent infusion of capital, CellProthera is poised to accelerate its development pipeline and expand its clinical trial initiatives. The major strategic investment suggests strong confidence from backers in the company's technology and its potential to disrupt the cardiac care market. This funding will likely be instrumental in advancing ProtheraCytes through further stages of clinical validation and regulatory approval, paving the way for broader market access. The company's commitment to cutting-edge cellular therapies indicates a strategic focus on long-term growth and establishing a dominant position in the regenerative medicine landscape.
See full CellProthera company page
